FRIEDMAN CATHY
Known title: DirectorCIK: 0001411874
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Lyell Immunopharma shares fall 27% over four weeks. The stock has dropped about 27% in the past month, prompting a Yahoo article that discusses factors that could support a recovery. The piece notes the recent price weakness and points to potential catalysts that may improve sentiment. The decline leaves the share price near a key support level and the RSI is low, indicating oversold conditions.
Transaction History
| SEER | ▲ Buy | Grant | 23,443 | $0 | 6/14/2023 | View on chart |
| SEER | ▲ Buy | Grant | 9,945 | $0 | 6/15/2022 | View on chart |
| LYEL | ▼ Sell | Other | 3,765,842 | $0 | 12/14/2021 | View on chart |
| LYEL | ▼ Sell | Other | 218,722 | $0 | 12/14/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Seer to Present Proteomics Data at HUPO 2026; CFO Transition Announced
Seer Inc. will share early results from its PRECISE-SG100K proteomics study with Nanyang Technological University at the HUPO 2026 conference. The company also announced a transition in its Chief Financial Officer role. These developments provide updates on the firm's scientific progress and leadership structure.
Seer to Present Proteomics Data at HUPO 2026; CFO Transition Announced. Seer Inc. will share early results from its PRECISE-SG100K proteomics study with Nanyang Technological University at the HUPO 2026 conference. The company also announced a transition in its Chief Financial Officer role. These developments provide updates on the firm's scientific progress and leadership structure.